Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco DB Agriculture Fund (DBA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco DB Agriculture Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.66 (market cap $39.89B), while Invesco DB Agriculture Fund trades at $27.81. The key difference: Invesco DB Agriculture Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DBA | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $28.73 |
52-Week Low | $278.09 | $25.44 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DBA (Invesco DB Agriculture Fund) trades at $27.77, up 0.22% today, with a bullish technical signal supported by moving averages but tempered by overbought oscillators. The ETF tracks agricultural commodities including corn, soybeans, wheat, and livestock, benefiting from recent supply disruptions and strong commodity price trends. Recent news highlights weather impacts on Brazilian coffee harvests and China's $17 billion U.S. crop purchase commitment through 2028.
The agricultural commodity exposure positions DBA for potential gains amid global supply constraints, though high RSI levels suggest near-term consolidation risk. Key support sits at $27 with resistance at $28-29. Investors should monitor crop reports and geopolitical developments affecting commodity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →
